PCSK9 and diabetes mellitus: For primary prevention of CVD in people with diabetes receiving a statin, the absolute benefit of PCSK9 inhibitors is estimated to be around 13–19 people who will avoid major cardiovascular events (per 1000 people treated for 5 years, assuming an annual event rate of 1–1.5%; Table 3).